
    
      The proposed clinical trial will be a prospective, case-controlled Phase I, open label,
      single site study. The first 10 consecutively enrolled patients will receive CYCLOTEC
      standard procedure thyroid imagery and an additional whole-body scans, and 20 subsequent
      case-matched controls, will receive GPERT and will also have additionnal whole body scan.
    
  